covalent inhibitor
A covalent inhibitor is a drug that does not just nestle into its target but actually forms a chemical bond with it, locking on for the long haul. Most drugs bind reversibly — they drift in and out like a key turning loosely in a lock. A covalent inhibitor instead reacts with a specific amino acid on the target and stays welded there, so the protein remains blocked until the cell makes a brand-new copy.
The trick is to combine two things: a part of the molecule that recognizes and sits snugly in the target's pocket, and a mildly reactive group, the warhead, that then snaps a bond to a nearby reactive residue, usually a cysteine. The recognition has to come first; if the warhead were too reactive on its own, it would bond to random proteins all over the body and cause toxicity.
Covalent inhibitors offer durable, near-permanent target shutdown and can stay effective at lower doses, which is attractive for hard-to-drug targets. The flip side is that any off-target bonding is also permanent, raising safety concerns, and irreversible binding can sometimes provoke immune reactions. Careful warhead tuning is what separates a clean covalent drug from a hazardous one.
Ibrutinib covalently binds a cysteine in the BTK kinase, and sotorasib covalently traps the mutant KRAS G12C — both rely on a cysteine that happens to sit beside the binding pocket.
Two covalent drugs that each react with a target cysteine.
Not all covalent inhibitors are irreversible. Some "reversible covalent" drugs form a bond that can slowly break again, aiming for the durability of a covalent bond without the permanence of off-target damage.